Delving into the Latest Updates on Bumetanide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid, 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid, 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid

+ [19]

Target

NKCC1 x NKCC2 x SLC12A4

Mechanism

NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors), SLC12A4 inhibitors(solute carrier family 12 member 4 inhibitors)

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Heart FailureHypercalcemiaHyperkalemia+ [4]

Inactive Indication

Autism Spectrum Disorder

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization

Guilin Pharmaceutical Group Co., Ltd.

Knight Therapeutics, Inc.Chemidex Pharma Ltd.

+ [2]

Inactive Organization

Adir SRLInstitut de Recherches Intern Servier

Drug Highest PhaseApproved

First Approval Date

JP (08 Apr 1976),

Edema

Regulation-

Login to view timeline

Structure

Molecular FormulaC17H20N2O5S

InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N

CAS Registry28395-03-1

主要研究目的研究空腹和餐后单次口服布美他尼片受试制剂（规格：1mg，新乡市常乐制药有限责任公司生产，浙江和沐康医药科技有限公司提供）与布美他尼片参比制剂（Burinex®，规格：1mg，Karo Pharma AB持证，浙江和沐康医药科技有限公司提供）在中国健康受试者体内的药代动力学行为，评价空腹及餐后口服两种制剂的生物等效性。次要研究目的评价中国健康受试者空腹和餐后单次口服受试制剂（T）布美他尼片和参比制剂（R）布美他尼片（Burinex®）后的安全性。

[Translation]

Main study objectives To study the pharmacokinetic behavior of the test formulation of bumetanide tablets (specification: 1 mg, produced by Xinxiang Changle Pharmaceutical Co., Ltd., provided by Zhejiang Hemukang Pharmaceutical Technology Co., Ltd.) and the reference formulation of bumetanide tablets (Burinex®, specification: 1 mg, licensed by Karo Pharma AB, provided by Zhejiang Hemukang Pharmaceutical Technology Co., Ltd.) in Chinese healthy subjects after single oral administration on an empty stomach and after a meal, and to evaluate the bioequivalence of the two formulations after oral administration on an empty stomach and after a meal. Secondary study objectives To evaluate the safety of the test formulation (T) bumetanide tablets and the reference formulation (R) bumetanide tablets (Burinex®) after single oral administration on an empty stomach and after a meal in Chinese healthy subjects.

Start Date27 Feb 2024

Sponsor / Collaborator

Zhejiang Hemukang Pharmaceutical Technology Co., Ltd.

NCT06036914 / Enrolling by invitationPhase 2IIT

Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial

The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.

Start Date27 Nov 2023

Sponsor / Collaborator

Mayo Clinic

NCT06052163 / RecruitingPhase 2IIT

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.

This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been proposed based on data that demonstrated its ability to "flip" the APOE genotype-dependent transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was subsequently explored in Electronic Health Record cohorts, which revealed that among individuals over the age of 65, bumetanide exposure was significantly associated with a lower prevalence of AD in three independent datasets.
Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to participants with biomarker-confirmed Alzheimer's disease.
Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Start Date10 Apr 2023

Sponsor / Collaborator

Stanford University

100 Clinical Results associated with Bumetanide

Login to view more data

100 Translational Medicine associated with Bumetanide

Login to view more data

100 Patents (Medical) associated with Bumetanide

Login to view more data

2,725

Literatures (Medical) associated with Bumetanide

01 Jan 2025·Progress in Neuro-Psychopharmacology and Biological Psychiatry

The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future

Review

Author: Mirabelli, Silvestro ; Cortese, Samuele ; Parlatini, Valeria ; Persico, Antonio M. ; Asta, Lisa ; Arango, Celso ; Chehbani, Fethia ; Vitiello, Benedetto ; Persico, Antonio M

Part I of this systematic review summarized the state-of-the-art of pediatric psychopharmacology for Autism Spectrum Disorder (ASD), a severe and lifelong neurodevelopmental disorder. The purpose of this Part II follow-up article is to provide a systematic overview of the experimental psychopharmacology of ASD. To this aim, we have first identified in the Clinicaltrials.gov website all the 157 pharmacological and nutraceutical compounds which have been experimentally tested in children and adolescents with ASD using the randomized placebo-controlled trial (RCT) design. After excluding 24 drugs already presented in Part I, a systematic review spanning each of the remaining 133 compounds was registered on Prospero (ID: CRD42023476555), performed on PubMed (August 8, 2024), and completed with EBSCO, PsycINFO (psychology and psychiatry literature) and the Cochrane Database of Systematic reviews, yielding a total of 115 published RCTs, including 57 trials for 23 pharmacological compounds and 48 trials for 17 nutraceuticals/supplements. Melatonin and oxytocin were not included, because recent systematic reviews have been already published for both these compounds. RCTs of drugs with the strongest foundation in preclinical research, namely arbaclofen, balovaptan and bumetanide have all failed to reach their primary end-points, although efforts to target specific patient subgroups do warrant further investigation. For the vast majority of compounds, including cannabidiol, vasopressin, and probiotics, insufficient evidence of efficacy and safety is available. However, a small subset of compounds, including N-acetylcysteine, folinic acid, l-carnitine, coenzyme Q10, sulforaphane, and metformin may already be considered, with due caution, for clinical use, because there is promising evidence of efficacy and a high safety profile. For several other compounds, such as secretin, efficacy can be confidently excluded, and/or the data discourage undertaking new RCTs. Part I and Part II summarize "drug-based" information, which will be ultimately merged to provide clinicians with a "symptom-based" consensus statement in a conclusive Part III, with the overarching aim to foster evidence-based clinical practices and to organize new strategies for future clinical trials.

01 Dec 2024·Glia

Endothelin‐1 increases Na⁺‐K⁺‐2Cl⁻ cotransporter‐1 expression in cultured astrocytes and in traumatic brain injury model: An involvement of HIF1α activation

Article

Author: Fukui, Yura ; Izumi, Yasuhiko ; Fujimoto, Rina ; Hosogi, Nami ; Hishinuma, Shigeru ; Michinaga, Shotaro ; Koyama, Yutaka ; Ogawa, Yasuhiro ; Takahashi, Kenta ; Hamada, Yasuhiro

AbstractNa+‐K+‐2Cl− cotransporter‐1 (NKCC1) is present in brain cells, including astrocytes. The expression of astrocytic NKCC1 increases in the acute phase of traumatic brain injury (TBI), which induces brain edema. Endothelin‐1 (ET‐1) is a factor that induces brain edema and regulates the expression of several pathology‐related genes in astrocytes. In the present study, we investigated the effect of ET‐1 on NKCC1 expression in astrocytes. ET‐1 (100 nM)‐treated cultured astrocytes showed increased NKCC1 mRNA and protein levels. The effect of ET‐1 on NKCC1 expression in cultured astrocytes was reduced by BQ788 (1 μM), an ETB antagonist, but not by FR139317 (1 μM), an ETA antagonist. The involvement of ET‐1 in NKCC1 expression in TBI was examined using a fluid percussion injury (FPI) mouse model that replicates the pathology of TBI with high reproducibility. Administration of BQ788 (15 nmol/day) decreased FPI‐induced expressions of NKCC1 mRNA and protein, accompanied with a reduction of astrocytic activation. FPI‐induced brain edema was attenuated by BQ788 and NKCC1 inhibitors (azosemide and bumetanide). ET‐1‐treated cultured astrocytes showed increased mRNA and protein expression of hypoxia‐inducible factor‐1α (HIF1α). Immunohistochemical observations of mouse cerebrum after FPI showed co‐localization of HIF1α with GFAP‐positive astrocytes. Increased HIF1α expression in the TBI model was reversed by BQ788. FM19G11 (an HIF inhibitor, 1 μM) and HIF1α siRNA suppressed ET‐induced increase in NKCC1 expression in cultured astrocytes. These results indicate that ET‐1 increases NKCC1 expression in astrocytes through the activation of HIF1α.

01 Dec 2024·The American Journal of Emergency Medicine

Epidemiology of heart failure presentations to United States emergency departments from 2016 to 2023

Article

Author: Bernard, Kyle ; Gottlieb, Michael ; Moyer, Eric

INTRODUCTIONHeart failure (HF) is a common condition prompting presentation to the Emergency Department (ED) and is associated with significant morbidity and mortality. However, there is limited recent large-scale, robust data available on the admission rates, evaluation, and treatment of HF in the ED setting.METHODSThis was a cross-sectional study of ED presentations for HF from 1/1/2016 to 12/31/2023 using the Epic Cosmos database. All ED visits with ICD-10 codes corresponding to acute HF were included. We excluded congenital heart disease and isolated right-sided HF. Outcomes included percentage of total ED visits, admission rates, troponin, B-type natriuretic peptide (BNP), chest radiography, and diuretic and nitroglycerin medication administration. Subgroup analyses of medications were performed by medication and route of administration (transdermal, sublingual/oral, and intravenous).RESULTSOut of 190,694,752 ED encounters, 2,626,011 (1.4 %) visits were due to acute HF. Of these, 1,897,369 (72.3 %) were admitted to the hospital. The majority of patients had a troponin (90.3 %), BNP (91.1 %), and chest radiograph (89.5 %) ordered. 82.5 % received intravenous diuresis, while 46.2 % received oral diuresis. The most common diuretic was furosemide (78.4 % intravenous, 32.5 % oral), followed by bumetanide (9.5 % intravenous, 7.1 % oral), and torsemide (0 % intravenous, 8.1 % oral). Nitroglycerin was given in 26.0 %, with the most common route being sublingual/oral (16.6 %), followed by transdermal (9.2 %) and intravenous (3.5 %).CONCLUSIONHF represents a common reason for ED presentation, with the majority of patients being admitted. All patients received diuresis in the ED, with the majority receiving intravenous diuresis with furosemide. Approximately one-quarter received nitroglycerin with the sublingual/oral route being most common. These findings can help inform health policy initiatives, including admission decisions and evidence-based medication administration.

4

News (Medical) associated with Bumetanide

28 Jun 2024

·www.globenewswire.com

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptoms June 27, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The results of the study were published in the peer-reviewed journal Biomedicines, in an article titled “Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD”. Lynn Durham, CEO of STALICLA, highlighted: “This study marks a significant milestone in the advancement of precision medicine for ASD. It is a first-of-its-kind stratification-based approach for clinical development in neurodevelopmental disorders, demonstrating the potential of precision medicine in ASD.” The randomized, double-blind, placebo-controlled phase 1b clinical trial evaluated the safety and tolerability of STP1, a combination of ibudilast and bumetanide, in ASD-Phen1 patients. The clinical trial (registered at clinicaltrials.gov NCT04644003), involved two 14-day treatment phases of ASD-Phen1 patients receiving STP1 or placebo. The results showed that STP1 was well-tolerated with no significant adverse effects reported. Significant and dose-related reductions in gamma power were observed in the whole brains of patients taking STP1, particularly in regions associated with executive function and memory. Additionally, STP1 increased alpha 2 power in frontal and occipital regions, while improving habituation and neural synchronization to auditory chirps. Dr. Craig A. Erickson, Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Medical Center, and the principal investigator of the study, remarked: “The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field.” Dr. Laura Pérez-Cano, Head of Discovery at STALICLA and co-author of the study, added: “These findings not only highlight the potential of STP1 as a therapeutic option for ASD-Phen1 patients but also underscore the importance of combining biologically-based patient stratification with quantifiable outcome measures such as EEG that can then be correlated with behavioral measures.” By focusing on a biologically defined subgroup of ASD patients, STALICLA is moving closer to making personalized treatment options a reality for patients with ASD. This approach has the potential to revolutionize the treatment of ASD and other neuropsychiatric conditions. STALICLA is a global, clinical-stage biotechnology company focused on advancing precision medicine for brain disorders. The company has developed a unique neuro precision development platform, DEPI, supported by clinical validation in a first indication: Autism Spectrum Disorder. Its lead neurodevelopmental disorder asset, STP1, is entering Phase 2 trials. Its lead neuropsychiatry asset, STP7 (Mavoglurant), fully funded by the US government, will soon be Phase 3 ready for Cocaine Use Disorder. ‎ The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

17 Jan 2024

·www.pharmaceutical-technology.com

Stalica raises $17.5m to advance neurology programmes

The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. Image Credit: Alex and Maria photo / Shutterstock. Switzerland-based Stalica has raised $17.5m in Series B financing to fund clinical trials for its neuropsychiatric and neurological disorders pipeline. The clinical programmes that the company plans to use the Series B proceeds include the fixed-dose combination drug STP1 and mavoglurant (STP7). Furthermore, the company will also strengthen the data package for STP2. Stalica’s clinical pipeline STP1 is a fixed dose combination of ibudilast, a phosphodiesterase (PDE) 4/3 inhibitor, and bumetanide, a sodium (Na)- potassium (K)- chloride (Cl) cotransporter (NKCC) 1 agonist. Stalica is developing the precision therapy as a treatment for autism spectrum disorder (ASD) in a specific sub-group of patients, phenotype 1 (Phen1). Phen1 patients have been identified by Stalica and validated using two independent clinical observational/bio-sampling studies (NCT05590715 and NCT04644003). The company is planning a Phase II trial for STP1 in patients with ASD, the preparation of which will be funded by the proceeds from the current financing round. Mavoglurant is a negative allosteric modulator of the glutamate receptor 5 (mGluR5). Stalica signed an in-licencing agreement with Novartis to develop the drug as a treatment for substance-use disorders and neurodevelopmental disorders (NDDs) in January 2023. As per the agreement, the company is entitled to receive up to $270m in upfront and milestone-based payments along with royalties on net sales. The company is planning a Phase III trial for mavoglurant in patients with cocaine use disorder in 2025. The trial will be funded by the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). It is expected to enrol up to 330 patients. STP2 is a stabilised synthetic form of sulforaphane. Stalica acquired the rights to the therapy from the UK-based Evgen Pharma in October 2022. Stalica is developing STP2 as a treatment for ASD in Phen2 sub-population. The company plans to start Phase II trial for the therapy in 2023. ASD landscape The total diagnosed prevalence of ASD was more than 9.81 million in 2023 and is expected to be approximately 9.65 million diagnosed prevalent cases of ASD in 2028, as per a 2023 Globaldata report . The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. GlobalData is the parent company of Pharmaceutical Technology . In November 2023, SciSparc started a clinical trial for SCI-210 to treat ASD symptoms in children. SCI-210 is a combination of cannabidiol (CBD) and palmitoylethanolamide. The trial is expected to enrol 60 patients aged five and 18 years. Apart from ASD treatment, strides have been made in developing diagnostics for the disorder. In September 2023, EarliTech positive data from two studies showing the efficacy and accuracy of its EarliPoint Evaluation device in diagnosing and assessing autism in children aged 30 months and older.

Phase 2Phase 3

10 Jan 2023

·www.biospace.com

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

MAHWAH, N.J., Jan. 10, 2023 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex®1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals, Inc. Commenting on the launch, Vijay Raghavan, Senior Vice President, Business Development Portfolio, Product Launch & Strategy, said, "We are very pleased to bring to market a lower cost alternative to Bumex® Injection, 0.25 mg/mL. This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark's continued focus on institutional business." According to IQVIATM sales data for the 12-month period ending November 2022, the Bumex® Injection, 0.25 mg/mL market2 achieved annual sales of approximately $16.5 million*. Glenmark's current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. About Glenmark Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is an innovation–driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world–class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world's top 100 biopharmaceutical companies (Top 100 Companies Ranked by Research and Development, and Pharmaceutical Sales, 2021, by In Vivo/Scrip 100); and among the world's top 50 companies in the off–patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2021, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world's most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit , LinkedIn (Glenmark Pharmaceuticals), Instagram (glenmark_pharma). References 1 All brand names and trademarks are the property of their respective owners. 2 Market includes brand and all available therapeutic equivalents * IQVIATM National Sales Perspectives: Retail & Non-Retail, November 2022 Logo: Company Codes: Bombay:532296, Bombay:GLENMARK.BO, India:GLENMARK.NS

Drug Approval

100 Deals associated with Bumetanide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00247	Bumetanide	C03CA02	DB00887

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	CA	Knight Therapeutics, Inc.	31 Dec 1993
Hypercalcemia	CN	Guilin Pharmaceutical Group Co., Ltd.	01 Jan 1982
Hyperkalemia	CN	Guilin Pharmaceutical Group Co., Ltd.	01 Jan 1982
Hypertension	CN	Guilin Pharmaceutical Group Co., Ltd.	01 Jan 1982
Hyponatremia	CN	Guilin Pharmaceutical Group Co., Ltd.	01 Jan 1982
Poisoning	CN	Guilin Pharmaceutical Group Co., Ltd.	01 Jan 1982
Edema	JP	Daiichi Sankyo Co., Ltd.	08 Apr 1976

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autism Spectrum Disorder	Phase 2	NL	Adir SRL	24 Sep 2018
Autism Spectrum Disorder	Phase 2	FR	Institut de Recherches Intern Servier	24 Sep 2018
Autism Spectrum Disorder	Phase 2	PL	Adir SRL	24 Sep 2018
Autism Spectrum Disorder	Phase 2	PT	Adir SRL	24 Sep 2018
Autism Spectrum Disorder	Phase 2	GB	Institut de Recherches Intern Servier	24 Sep 2018
Autism Spectrum Disorder	Phase 2	NL	Institut de Recherches Intern Servier	24 Sep 2018
Autism Spectrum Disorder	Phase 1	ES	Adir SRL	24 Sep 2018
Autism Spectrum Disorder	Phase 1	HU	Institut de Recherches Intern Servier	24 Sep 2018
Autism Spectrum Disorder	Phase 1	FR	Adir SRL	24 Sep 2018
Autism Spectrum Disorder	Phase 1	DE	Institut de Recherches Intern Servier	24 Sep 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03715153 (CTgov)	Phase 3	Autism Spectrum Disorder	211	BUMETANIDE (S95008) for week 0 - 26 (BUMETANIDE (S95008) Followed by Open-Label S95008)	tkeczswtkw(gpiccvzfzf) = dilmnqbxhr ymanhghwbj (lrzlemjtci, emifugfnie - asyzduoatl) View more	-	05 Jun 2023
				PLACEBO for week 0 - 26+Open-Label BUMETANIDE (S95008) for weeks 26 - 52 (PLACEBO Followed by Open-Label S95008)	tkeczswtkw(gpiccvzfzf) = hkapfanqwk ymanhghwbj (lrzlemjtci, vpvnohwucy - zvwxgkqcug) View more
NCT03923933 (HEBE-CKD, Pubmed)	Phase 2	Chronic Kidney Diseases	34	Bumetanide plus chlorthalidone	znxzkygcfc(vaqhxqhzbm) = xihrnjevbo qjsulsfygu (ykdqmegayq ) View more	-	20 Sep 2022
				Bumetanide plus placebo	znxzkygcfc(vaqhxqhzbm) = tsliwlpzbn qjsulsfygu (ykdqmegayq ) View more
HEBE Trial (ASN2020)	Phase 4	Chronic Kidney Diseases	-	Bumetanide 2 mg BID + Chlorthalidone 50 mg BID	(dsyglcbxue) = eavofrebjn pkbgyfscbm (bmqvudjjnc, 10.7) View more	Positive	19 Oct 2020
				Bumetanide 2 mg BID + Placebo	(dsyglcbxue) = ksgxuhrywy pkbgyfscbm (bmqvudjjnc, 11.9) View more
HEBE-CKD Trial (ESC2020)	Not Applicable	Chronic Kidney Diseases	-	Bumetanide + Chlorthalidone	(mfngpznagp) = ihoglaxbmv ahdthidoap (rxozklfghj ) View more	Positive	30 Aug 2020
				Bumetanide + Placebo	(mfngpznagp) = wnvfbpgogf ahdthidoap (rxozklfghj ) View more
EULAR2020	Not Applicable	Acute congestive heart failure	130	Intravenous Bumetanide	ervrdhqvyq(wrxjwriyoj) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares ksjmxntqzk (csvdqgkgef ) View more	-	03 Jun 2020
NCT03923933 (HEBE-CKD, CTgov)	Phase 2	Chronic Kidney Diseases	34	Bumetanide (Placebo)	jvdppeevai(sszqrjwllw) = xqogarfkpr uyvoqvmosd (ugaviywsgf, jninutorso - migjuunxqf) View more	-	10 Mar 2020
				Bumetanide+Chlorthalidone (Treatment Grup)	jvdppeevai(sszqrjwllw) = qihmveydch uyvoqvmosd (ugaviywsgf, htzczhfthj - rembcevxrq) View more
NCT01973335 (DIURESIS-CHF, CTgov)	Phase 4	Heart Failure	34	oral spironolactone+Combination therapy (Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone)	emxxssgjwe(ttldftklzc) = xprnmjvkqx ohsouhrxkd (aejjeozrle, alhmqwoaun - dpnbuzwzqp) View more	-	21 Mar 2019
				oral spironolactone+High-dose loop diuretics (High-dose Loop Diuretics, Upfront Spironolactone)	emxxssgjwe(ttldftklzc) = cfkgrjzgix ohsouhrxkd (aejjeozrle, hseqqftnak - cmtciobxcd) View more
ANA2018	Not Applicable	Epilepsy, Benign Neonatal Add-on	-	Phenobarbital + Placebo	npjsrxhibu(tcixivyhye) = p=0.02 qfhjrnkskd (bpexrmbfvr ) View more	Positive	05 Oct 2018
				Phenobarbital + Bumetanide 0.1mg/kg
ESC2017	Not Applicable	Heart Failure	-	Furosemide	(jcplbtumpo) = yaskhrhmqc rbypgwboko (oafosuattu )	-	27 Aug 2017
				Bumetanide	(jcplbtumpo) = kcbsxkmixq rbypgwboko (oafosuattu )
ANA2015	Not Applicable	Seizures Adjuvant	-	Bumetanide 0.1mg/kg	(ugdtvbcgqv) = comparable between subjects receiving bumetanide vs. phenobarbital alone zhqzfwlscn (qjfurfotyx ) View more	Positive	25 Sep 2015
				Bumetanide 0.2mg/kg